AG 494 - CAS 139087-53-9
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
AG 494
Catalog Number:
139087-53-9
Synonyms:
alpha-Cyano-(3,4-dihydroxy)-N-phenylcinnamide; Tyrphostin AG-494; Tyrphostin B48
CAS Number:
139087-53-9
Description:
AG-494 is a EGFR (epidermal growth factor receptor) kinase inhibitor with IC50 value of 0.7 μM. It is selective over ErbB2, PDGFR and insulin receptor kinase (IC50 values are 42, 6 and > 100 μM respectively). AG-494 tyrphostin also can block Cdk2 activation.
Molecular Weight:
280.28
Molecular Formula:
C16H12N2O3
Quantity:
Milligrams-Grams
Quality Standard:
In-house standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
C(\C(=C\c1cc(c(cc1)O)O)C#N)(=O)Nc1ccccc1
InChI:
1S/C16H12N2O3/c17-10-12(8-11-6-7-14(19)15(20)9-11)16(21)18-13-4-2-1-3-5-13/h1-9,19-20H,(H,18,21)/b12-8+
InChIKey:
HKHOVJYOELRGMV-XYOKQWHBSA-N
Targets:
EGFR
Chemical Structure
CAS 139087-53-9 AG 494

Related EGFR Products


CAS 1421373-65-0 AZD-9291

AZD-9291
(CAS: 1421373-65-0)

AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...

CAS 1421373-62-7 Mutant EGFR inhibitor

Mutant EGFR inhibitor
(CAS: 1421373-62-7)

AZD3759
(CAS: 1626387-80-1)

AZD3759 is a n orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3...

CAS 257933-82-7 Pelitinib

Pelitinib
(CAS: 257933-82-7)

Pelitinib is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. EKB-569 irreversibly binds covalently to epidermal gr...

CAS 153436-53-4 AG-1478

AG-1478
(CAS: 153436-53-4)

AG-1478 (NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM; almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

CAS 451492-95-8 MP-412

MP-412
(CAS: 451492-95-8)

MP-412 (AV-412) is a second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to an...

CAS 1213269-23-8 WZ-4002

WZ-4002
(CAS: 1213269-23-8)

Naquotinib mesylate
(CAS: 1448237-05-5)

Naquotinib is irreversible, third-generation, epidermal growth factor receptor (EGFR) inhibitor with IC50 value of 70 nM for NCI-H1650 cell growth. It can coval...

CAS 183322-45-4 PD153035 HCl

PD153035 HCl
(CAS: 183322-45-4)

PD153035 is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.

CAS 248594-19-6 Erlotinib mesylate

Erlotinib mesylate
(CAS: 248594-19-6)

Erlotinib is an EGFR inhibitor. The drug follows Iressa (gefitinib), which was the first drug of this type. Erlotinib specifically targets the epidermal growth ...

Tarloxotinib bromide
(CAS: 1636180-98-7)

Tarloxotinib bromide, a pyridopyrimidine derivative, has been found to be a EGFR tyrosine kinase inhibitor precursor and could probably be effective in antineop...

CAS 714971-09-2 AC480

AC480
(CAS: 714971-09-2)

AC480, also known as BMS-599626, is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50 =22, 32 and 190 nM, respectively) with po...

CGP-59326
(CAS: 173458-56-5)

CGP-59326, a pyrrolopyrimidine derivative, has been found to be an EGFR antagonist and could used in antineoplastic studies.

CAS 859853-30-8 BMS-6690514

BMS-6690514
(CAS: 859853-30-8)

BMS-690514 is a potent inhibitor of human epidermal growth factor receptor (HER) 1 (EGFR), 2, and 4, and vascular endothelial growth factor receptors (VEGFR) 1-...

CAS 845272-21-1 Varlitinib

Varlitinib
(CAS: 845272-21-1)

Varlitinib, also known as ARRY-543, is an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. V...

CAS 1092364-38-9 Poziotinib

Poziotinib
(CAS: 1092364-38-9)

Poziotinib, also known as HM781-36B and NOV120101, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor wit...

CAS 937265-83-3 ARRY-380

ARRY-380
(CAS: 937265-83-3)

ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.

CAS 183319-69-9 Erlotinib hydrochloride

Erlotinib hydrochloride
(CAS: 183319-69-9)

Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA M...

CAS 781613-23-8 XL-647

XL-647
(CAS: 781613-23-8)

XL647 is an orally bioavailable small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. It inhibits EGFR, HER2, VEGFR and EphB...

CAS 1421372-66-8 AZD9291DA HCl salt

AZD9291DA HCl salt
(CAS: 1421372-66-8)

AZD9291-DA is a des acryl analogue of AZD9291, which is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients ...

Reference Reading


1.The inhibitory mechanisms of the tyrosine kinase inhibitors herbimycin a, genistein, and tyrphostin B48 with regard to the function of the aryl hydrocarbon receptor in Caco-2 cells.
Kasai S1, Kikuchi H. Biosci Biotechnol Biochem. 2010;74(1):36-43. Epub 2010 Jan 7.
The aryl hydrocarbon receptor (AhR) is a transcription factor that is activated by dioxin and related xenobiotics. Although the activation of AhR is inhibited by tyrosine kinase inhibitors, the molecular mechanism has not been clarified. In the current study, the inhibitory mechanisms of several inhibitors of tyrosine kinase, herbimycin A, genistein, and tyrphostin B48, on AhR activation was analyzed in human Caco-2 cells. All the inhibitors suppressed the transcriptional activation of AhR induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Herbimycin A induced down-regulation of the AhR protein by inhibiting its molecular chaperone heat shock protein 90 (HSP90). In contrast, genistein and tyrphostin B48 inhibited the nuclear localization of AhR induced by TCDD, although the amount of AhR protein was not altered. The inhibitory effects of genistein and tyrphostin B48 on endogenous tyrosine kinase activity were evaluated by detection of alterations in the tyrosine phosphorylation states of cellular proteins.
2.Tyrphostin AG 494 blocks Cdk2 activation.
Osherov N1, Levitzki A. FEBS Lett. 1997 Jun 30;410(2-3):187-90.
We have previously shown that the EGFR kinase selective tyrphostin AG 494 fails to inhibit EGFR kinase in intact cells. Yet, AG 494 proved to inhibit EGF- or serum-induced cell proliferation (Osherov et al., J. Biol. Chem. 268 (1993) 11134-11142). In this preliminary communication we show that AG 494 as well as its close analogs AG 490 and AG 555 block Cdk2 activation. In contrast, AG 1478, a more selective EGFR kinase blocker which is also active as EGFR kinase blocker in intact cells, fails to do so. AG 494 exerts its full inhibitory activity on Cdk2 activation even when added 20 h subsequent to EGF addition when Cdk2 activation is maximal. The inhibitory activity on Cdk2 activation parallels its DNA synthesis inhibitory activity, strongly suggesting that its target is one of the molecular mechanisms involved in Cdk2 activation. AG 494 and its analogs may become useful lead compounds for the development of drugs aimed at the cell cycle machinery.